Npp1 fusion proteins

Abstract

The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.

1 - 38 . (canceled) 
     
     
         39 . An isolated polypeptide comprising a targeting moiety and a catalytic domain of NPP1, wherein said catalytic domain of NPP1 comprises the amino acid sequence set forth from P99 to D925 of SEQ ID NO:1. 
     
     
         40 . The polypeptide of  claim 39 , wherein said targeting moiety is a peptide comprising about five to about eighteen consecutive negatively charged amino acid residues. 
     
     
         41 . The polypeptide of  claim 39 , wherein said negatively charged amino acid residues are aspartic acid or glutamic acid. 
     
     
         42 . The polypeptide of  claim 41 , wherein said negatively charged amino acid residues comprise about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 consecutive aspartic acid or glutamic acid residues. 
     
     
         43 . The polypeptide of  claim 42 , wherein said negatively charged amino acid residues comprise about eight consecutive aspartic acid residues. 
     
     
         44 . The polypeptide of  claim 42 , wherein said negatively charge amino acid residues comprises about ten consecutive aspartic acid residues. 
     
     
         45 . The polypeptide of  claim 41 , wherein said negatively charged amino acid residues comprise about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 consecutive aspartic acid residues. 
     
     
         46 . The polypeptide of  claim 45 , wherein said negatively charged amino acid residues comprise about eight consecutive glutamic acid residues. 
     
     
         47 . The polypeptide of  claim 45 , wherein said negatively charge amino acid residues comprises about ten consecutive glutamic acid residues. 
     
     
         48 . The polypeptide of  claim 39 , wherein said targeting moiety is fused to C-terminus of said catalytic domain of NPP1. 
     
     
         49 . The polypeptide of  claim 42 , wherein said polypeptide further comprises an Fc region of an immunoglobulin. 
     
     
         50 . The polypeptide of  claim 49 , wherein said Fc region comprises the amino acid sequence set forth in SEQ ID NO:16. 
     
     
         51 . The polypeptide of  claim 50 , wherein said targeting moiety is ten consecutive aspartic acid residues. 
     
     
         52 . The polypeptide of  claim 49 , wherein said Fc region is fused to C-terminus of said catalytic domain of NPP1. 
     
     
         53 . The polypeptide of  claim 39 , wherein said polypeptide further comprises a signal peptide.